Clinical trial
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast…
NCT00054275 · Paula Silverman, MD, Other · Completed
Key facts
| NCT number | NCT00054275 |
|---|---|
| Title | Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer |
| Official title | A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With The Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer |
| Lead sponsor | Paula Silverman, MD, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, erlotinib hydrochloride |
| Enrollment | 39 |
| Start date | Dec 1, 2002 |
| Primary completion | Apr 1, 2010 |
| Completion | Nov 1, 2012 |
| First posted | Feb 6, 2003 |
| Last update posted | Feb 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: